Prevail Therapeutics
OverviewSuggest Edit
Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease. It establishes a pipeline of programs that includes discovery-phase and preclinical development efforts.
| Type | Public | |
| Founded | 2017 | |
| HQ | New York, US | Map |
| Website | prevailtherapeutics.com |
Recent NewsAll News
- Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001
- Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
- Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
- Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
Key People/Management at Prevail Therapeutics
Asa Abeliovich
CEO & Founder, Director
Franz Hefti
Chief Development Officer
Yong Dai
Chief Technology Officer
Jeffrey Sevigny
Chief Medical Officer
Brett Kaplan
Chief Financial Officer
Emily Minkow
Chief Business Officer
Prevail Therapeutics Office Locations
Prevail Therapeutics has an office in New York
New York, US (HQ)
430 E 29th St #940
Prevail Therapeutics Financials and Metrics
Prevail Therapeutics Revenue
| USD | |
|---|---|
Net income (Q2, 2020) | (22.1m) |
EBIT (Q2, 2020) | (22.2m) |
Market capitalization (20-Nov-2020) | 347.3m |
Closing stock price (20-Nov-2020) | 10.1 |
Cash (30-Jun-2020) | 111.1m |
EV | 246.8m |
Prevail Therapeutics's current market capitalization is $347.3 m.
Annual
Annual
Annual
| USD | FY, 2017 |
|---|---|
Debt/Equity | 1.7 x |
Debt/Assets | 0.3 x |
Financial Leverage | 5.5 x |
Prevail Therapeutics Cybersecurity Score
Prevail Therapeutics Online and Social Media Presence
Prevail Therapeutics's Trends
Prevail Therapeutics News and Updates
November 19, 2020
Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the United States Patent and Trademark Office (USPTO) o…
November 13, 2020
Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations
August 11, 2020
Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
Preliminary Data Demonstrates Normalization of CSF GBA1 Enzyme Activity in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease Patients
March 26, 2020
Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
Dosing Initiated in PROPEL Phase 1/2 Trial of PR001 for Treatment of Parkinson’s Disease with GBA1 Mutations
February 21, 2020
Prevail Therapeutics to Present at Upcoming Conferences
NEW YORK, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that management will present at…
December 26, 2019
Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease
NEW YORK, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Adm…
Prevail Therapeutics Blogs
November 02, 2020
Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO
Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO
Content Import
Mon, 11/02/2020 - 07:02
Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO
November 2, 2020 at 7:00 AM …
September 18, 2020
Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Liz.McPherson@…
Fri, 09/18/2020 - 15:05
Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 18, 2020 at 3:04 PM EDT
…
September 10, 2020
Prevail Therapeutics Announces Appointment of William H. Carson, M.D., to Board of Directors
NEW YORK , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the appointment of William H.
August 05, 2020
Prevail Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results
Prevail Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results
Content Import
Wed, 08/05/2020 - 16:03
Prevail Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results
August 5, 2020 at 4:01 PM EDT
This release …
July 22, 2020
Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative Diseases at the Virtual 2020 Alzheimer’s Association International Conference
Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative Diseases at the Virtual 2020 Alzheimer’s Association International Conference
Content Import
Wed, 07/22/2020 - 17:01
Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative…
June 04, 2020
Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel
Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel
Content Import
Thu, 06/04/2020 - 07:01
Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel
June 4, 2020 at 7:00 AM EDT
This release is a backfill from a News Wire
…
Prevail Therapeutics Frequently Asked Questions
When was Prevail Therapeutics founded?
Prevail Therapeutics was founded in 2017.
Who are Prevail Therapeutics key executives?
Prevail Therapeutics's key executives are Asa Abeliovich, Franz Hefti and Yong Dai.
How many employees does Prevail Therapeutics have?
Prevail Therapeutics has 48 employees.
Who are Prevail Therapeutics competitors?
Competitors of Prevail Therapeutics include Molecular Partners, NeuroVive Pharmaceutical and ViewPoint Therapeutics.
Where is Prevail Therapeutics headquarters?
Prevail Therapeutics headquarters is located at 430 E 29th St #940, New York.
Where are Prevail Therapeutics offices?
Prevail Therapeutics has an office in New York.
How many offices does Prevail Therapeutics have?
Prevail Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies